Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from BioInvent International AB ( (SE:BINV) ).
BioInvent International AB announced that Vincent Ossipow has stepped down from its Board of Directors, effective immediately. Ossipow, who served on the board from 2016-2020 and 2021-2025, was praised for his leadership and contributions during critical growth phases. The board remains quorate with seven elected members, aligning with the company’s strategic focus on clinical development, which Ossipow endorses as beneficial for patients.
The most recent analyst rating on (SE:BINV) stock is a Buy with a SEK90.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a clinical-stage biotech company specializing in the discovery and development of novel, first-in-class immuno-modulatory antibodies for cancer therapy. The company is engaged in Phase 1/2 clinical trials for treating hematological cancer and solid tumors. BioInvent leverages its proprietary F.I.R.S.T™ technology platform to identify targets and antibodies, offering licensing and partnering opportunities. It generates revenue through research collaborations, license agreements, and antibody production for third parties.
Average Trading Volume: 74,122
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK2.04B
Learn more about BINV stock on TipRanks’ Stock Analysis page.